AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
157.39
-1.98 (-1.24%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close159.37
Open158.22
Bid155.00 x 1200
Ask0.00 x 800
Day's Range155.73 - 158.95
52 Week Range142.81 - 197.00
Volume2,480,034
Avg. Volume2,066,104
Market Cap53.425B
Beta (3Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-5.32
Earnings DateFeb 4, 2019 - Feb 8, 2019
Forward Dividend & Yield2.88 (1.74%)
Ex-Dividend Date2018-11-09
1y Target Est210.06
Trade prices are not sourced from all markets
  • Final trades: Allergan, Verizon, JPMorgan, Visa & Yelp
    CNBC Videos5 days ago

    Final trades: Allergan, Verizon, JPMorgan, Visa & Yelp

    The "Halftime Report" traders and CNBC's Jim Cramer discuss top stocks to watch for the second half.

  • How Bausch Health’s Financials Look in November
    Market Realist14 hours ago

    How Bausch Health’s Financials Look in November

    Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017, a ~4% YoY decline. Bausch Health generated revenues of $6.26 billion over the first nine months of this year compared to $6.56 billion in the same period the prior year, reflecting a ~5% YoY decline.

  • How Wall Street Analysts View Bausch Health in November
    Market Realist15 hours ago

    How Wall Street Analysts View Bausch Health in November

    On November 13, Bausch Health stock closed at $26.63, which is a ~1.60% increase from its prior close of $26.21 on November 12, 2018. On November 13, Bausch Health stock closed at $26.63, a ~92% increase from its 52-week low of $13.86 on November 15, 2017. On October 3, 2018, Bausch Health hit its 52-week high of $28.45.

  • Who’s Eyeing Editas Medicine?
    Market Realist16 hours ago

    Who’s Eyeing Editas Medicine?

    Editas Medicine (EDIT) is a leading genome editing company. The company’s product development strategy is to mainly target genetically defined diseases with a focus on debilitating illnesses.

  • ICR Hires BlackRock Executive to Lead Governance Advisory Solutions Group
    CorpGov.com16 days ago

    ICR Hires BlackRock Executive to Lead Governance Advisory Solutions Group

    Lyndon Park Joins ICR as Managing Director, Head of Governance Advisory Solutions By John Jannarone ICR has hired Lyndon Park, a former executive at BlackRock and Dimensional Fund Advisors, to lead its newly-launched Governance Advisory Solutions practice, the communications and advisory firm announced Thursday. The new group, which ICR established as it hired Mr. Park, […]

  • Thomson Reuters StreetEvents7 days ago

    Edited Transcript of AGN earnings conference call or presentation 30-Oct-18 12:30pm GMT

    Q3 2018 Allergan plc Earnings Call

  • 6 Pharmaceutical Stocks to Buy After the Midterms
    InvestorPlace8 days ago

    6 Pharmaceutical Stocks to Buy After the Midterms

    Despite massive gains for the Democrats in the midterm elections in the House of Representatives and on the state level, the Republicans managed to hold onto the Senate. This is good for big pharmaceutical stocks (if bad for pharmaceutical users). Had the Democrats won both the House and Senate, scrutiny over drug pricing and the actions of the largest pharmaceutical companies would have resumed.

  • Ironwood (IRWD) Q3 Earnings & Revenues Miss, Shares Down
    Zacks9 days ago

    Ironwood (IRWD) Q3 Earnings & Revenues Miss, Shares Down

    Ironwood Pharmaceuticals (IRWD) misses estimates for both earnings and sales in the third quarter. The company maintains its guidance for operating expenses.

  • Editas Medicine Makes Steady Progress in Another Solid Quarter
    Motley Fool9 days ago

    Editas Medicine Makes Steady Progress in Another Solid Quarter

    From filing its IND filing for EDIT-101 to new data on new engineered cell treatments, the genome editing company delivered just as promised in Q3.

  • Moody's9 days ago

    Allergan Funding SCS -- Moody's assigns Baa3 to Allergan's notes; stable outlook

    Moody's Investors Service ("Moody's") assigned a Baa3 rating to the new euro-denominated senior unsecured notes issued by Allergan Funding SCS, an indirect subsidiary of Allergan plc. There are no changes to the existing ratings of entities in the Allergan family including the Baa3 ratings on senior unsecured notes at Allergan Funding SCS, Allergan Finance, LLC, Allergan Sales, LLC, and Allergan, Inc.. The rating outlook is stable.

  • Editas Medicine, Inc. (EDIT) Q3 2018 Earnings Conference Call Transcript
    Motley Fool9 days ago

    Editas Medicine, Inc. (EDIT) Q3 2018 Earnings Conference Call Transcript

    EDIT earnings call for the period ending September 30, 2018.

  • Teva Pharmaceutical’s Performance in the Third Quarter
    Market Realist12 days ago

    Teva Pharmaceutical’s Performance in the Third Quarter

    In the third quarter, Teva Pharmaceutical’s (TEVA) revenue fell ~19% YoY (year-over-year) to $4.5 billion. In the first nine months of this year, Teva’s net revenue fell ~16% YoY to $14.3 billion from $17.0 billion.

  • How Wall Street Analysts View Teva Pharmaceutical
    Market Realist12 days ago

    How Wall Street Analysts View Teva Pharmaceutical

    In October, the FDA’s Oncologic Drugs Advisory Committee unanimously voted to recommend approving Teva Pharmaceutical’s (TEVA) and Celltrion’s Biologics License Application for CT-P10, a proposed biosimilar to Roche’s (RHHBY) Rituxan. The recommended approval of CT-P10 was for three indications: as a monotherapy for relapsed or refractory B-cell non-Hodgkin’s lymphoma as a first-line treatment for B-cell NHL in combination with chemotherapy as a second-line monotherapy for non-progressing B-cell NHL after cyclophosphamide-, vincristine-, or prednisone-based chemotherapy

  • PR Newswire12 days ago

    Allergan to Present at Credit Suisse 27th Annual Healthcare Conference

    DUBLIN , Nov. 5, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that Chief Commercial Officer William Meury will present at the Credit Suisse 27 ...

  • Simply Wall St.13 days ago

    4 Days Left Before Allergan plc (NYSE:AGN) Will Be Trading Ex-Dividend,

    Attention dividend hunters! Allergan plc (NYSE:AGN) will be distributing its dividend of US$0.72 per share on the 14 December 2018, and will start trading ex-dividend in 4 days time on Read More...

  • IPO Edge14 days ago

    Ride the Wellness Wave at Sea with Shares of this Unique Spa Operator

    One Spa World to Go Public through Merger with Haymaker Acquisition Corp By John Jannarone The cruise industry is sometimes fraught with dangerous waters. But now, investors have a better way to navigate them. Meet One Spa World (OSW), the dominant health and wellness company that operates spas aboard major cruise lines such as Carnival […]

  • IPO-Edge.com14 days ago

    Ride the Wellness Wave at Sea with Shares of this Unique Spa Operator

    One Spa World to Go Public through Merger with Haymaker Acquisition Corp By John Jannarone The cruise industry is sometimes fraught with dangerous waters. But now, investors have a better way to navigate them. Meet One Spa World (OSW), the dominant health and wellness company that operates spas aboard major cruise lines such as Carnival […]

  • Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO
    Zacks15 days ago

    Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO

    We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.

  • Teva (TEVA) Q3 Earnings Beat, 2018 EPS View Up, Shares Rise
    Zacks15 days ago

    Teva (TEVA) Q3 Earnings Beat, 2018 EPS View Up, Shares Rise

    Teva's (TEVA) shares up 15% despite mixed third-quarter results as it increases its earnings and free cash flow guidance for the full year.

  • TheStreet.com15 days ago

    Allergan Needs to Rebase on the Charts - Don't Rush It

    The big pharma stocks used to represent a safe haven trade when the broad stock market turned weak, TheStreet's Jim Cramer told viewers of "Mad Money" Thursday night. While many drug stocks rallied Thursday, that rally may be short-lived, Cramer noted. , but even after a beat-and-raise quarter, analysts are still questioning whether CEO Brent Saunders is bringing out value fast enough.

  • Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus
    Zacks15 days ago

    Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus

    Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.

  • TheStreet.com15 days ago

    A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

    Jim Cramer told his Mad Money viewers Thursday that investors don't have to choose. Cramer said this report might give the Federal Reserve the ammunition it needs to take a break from interest rate hikes and wait to see what happens next. The Fed is worried about inflation after all, but Cramer said with prices falling for oil, wood, metal and other commodities, inflation might just take care of itself.